JAK

Inhibitory Selectivity
Catalog No.Inhibitor Name JAK1JAK2JAK3Tyk2Other
A11041Ruxolitinib
***
****
A10241Tofacitinib Citrate
**
**
****
ROCK2,LCK
A10110AZD1480
****
A11082Fedratinib
****
FLT3,RET
A10095AT9283
****
****
***
Aurora B,Aurora A,Abl1
A10047AG-490
*
EGFR,ErbB2
A10263Momelotinib
***
***
*
A11795WP1066
*
STAT3
A11180TG101209
***
*
RET,FLT3
A10546Gandotinib
**
****
**
**
FLT3,FLT4,FGFR2
A11193NVP-BSK805 2HCl
**
****
***
***
A11329Baricitinib
***
***
**
A10104AZ 960
****
A12808CEP-33779
****
A12694Pacritinib
*
**
*
**
FLT3 (D835Y),FLT3
A14049WHI-P154
*
EGFR,Src,VEGFR
A12394XL019
*
****
*
*
PDGFRβ,FLT3,c-Kit
A14955S-Ruxolitinib
***
****
*
**
A13509ZM 39923 HCl
*
**
TGM2,EGFR
A14012Decernotinib
***
***
****
***
A14210Cerdulatinib
***
***
***
****
ARK5,MST1,Fms
A14232Filgotinib
***
**
*
*
A15911FLLL32
*
A11241BMS-911543
*
****
**
**
A14438Peficitinib
A13162GLPG0634 analogue
A12419Go6976
FLT3,PKCα,PKCβ1
A10247Curcumol
A11608WHI-P97
A13082PF-03394197 (oclacitinib)
***
***
**
**
A13457Pyridone 6 (JAK Inhibitor I)
***
****
****
A14132NSC 42834(JAK2 Inhibitor V, Z3)
A14390INCB39110 (Itacitinib)
A14405Solcitinib (GSK2586184)
A15134JANEX-1
*
A15362Cercosporamide
***
Mnk2, Mnk1
A15365TCS 21311
*
*
***
*
A15366ZM 449829
****
****
STAT-5, EGFR, CDK4
A15389NSC 33994
A16227ZM 39923
****
***
TGM2, EGFR

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



Items 1 to 25 of 51 total

per page
Page:
  1. 1
  2. 2
  3. 3

Set Descending Direction
Catalog No. Product Name Application Product Information
A15361

1,2,3,4,5,6-Hexabromocyclohexane

JAK2 inhibitor
1,2,3,4,5,6-Hexabromocyclohexane is a potent and specific inhibitor of JAK2 autophosphorylation.
A10047 SALE

AG-490

EGFR inhibitor
AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
A10095 SALE

AT9283

Aurora/JAK inhibitor
AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation.
A10104 SALE

AZ-960

JAK inhibitor
AZ-960 is a potent, selective and ATP competitive JAK2 inhibitor that inhibits JAK2 kinase with a Ki of 0.45 nM in vitro and induces growth arrest and apoptosis in adult T-cell leukemia (ATL) cell.
A10110 SALE

AZD1480

JAK Inhibitor
AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM.
A11329 SALE

Baricitinib (LY3009104)

JAK Inhibitor
Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
A15014

Baricitinib phosphate

JAK inhibitor
Baricitinib phosphate is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.
A11241 SALE

BMS-911543

JAK inhibitor
BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity.
A12808 SALE

CEP33779

JAK Inhibitor
CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM.
A15362

Cercosporamide

Mnk2/JAK3 inhibitor
Cercosporamide, an usnic amide, was originally identified in Cercosporidium henningsii as a host-selective phytotoxin and broad-spectrum antifungal agent and is a potent inhibitor of MAP-kinase interacting kinase-2 (Mnk2; IC50 = 11 nM), JAK3 (IC50 = 31), and Mnk1 (IC50 = 116 nM).
A14210 SALE

Cerdulatinib

multi-targeted tyrosine kinase inhibitor
Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively.
A15937

CHZ868

-
CHZ868 is a potent and selective type II JAK inhibitor which demonstrates activity in JAK inhibitor persistent cells, murine MPN models, and MPN patient samples.
A10241 SALE

CP-690550 (Tofacitinib citrate)

JAK-3 inhibitor
CP-690550 (Tofacitinib citrate) is an orally available, highly selective inhibitor of the Janus kinase (JAK) family of enzymes.
A15363

Cucurbitacin I

JAK2/STAT3 inhibitor
Cucurbitacin I, Cucumis sativus L. has been found to suppress levels of phosphotyrosine Stat3 (signal transducer and activator of transcription 3) in v-Src-transformed NIH 3T3 cells.
A10247 SALE

Curcumol

JAK inhibitor
Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
A10263 SALE

Cyt387 (Momelotinib)

JAK inhibitor
CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively.
A15056

CYT387 sulfate salt

JAK inhibitor
CYT387 sulfate salt is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.
A14012

Decernotinib

JAK3 inhibitor
Decernotinib is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex.
A14232 SALE

Filgotinib

JAK inhibitor
Filgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
A15911

FLLL32

JAK2 inhibitor
FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 uM.
A13162 SALE

GLPG0634

JAK inhibitor
GLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
A12419

Go 6976

PKC inhibitor
Go 6976 is a potent protein kinase C (PKC) inhibitor (IC50 = 7.9 nM).
A11041

INCB018424 (Ruxolitinib)

JAK1/2 Inhibitor
INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
A14390 SALE

INCB39110 (Itacitinib)

JAK1 Inhibitor
INCB39110 is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
A15134 SALE

JANEX-1

JAK3 inhibitor
Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78 ??M); has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.

Items 1 to 25 of 51 total

per page
Page:
  1. 1
  2. 2
  3. 3

Set Descending Direction